Key considerations for maximizing LV and AAV production in transient transfection workflows

Recombinant adeno-associated virus (AAV) and lentivirus (LV) are critical components of gene and cell therapies, which show incredible promise for the treatment of disease. Accordingly, the need for large-scale manufacture of safe and effective viral vectors has never been greater. 

Here, we present optimization strategies for generating higher AAV and LV titers in both adherent and suspension HEK 293 cells using the TransIT-VirusGEN® Transfection Reagent. In addition, we will introduce LV and AAV enhancers that further increase functional virus titers over previously optimized conditions and expand manufacturing capabilities for gene and cell therapies.

Attendees will learn:

• Critical parameters for optimizing viral vector production and how small process changes can significantly impact titers
• How VirusGEN® Transfection Kits supports gene and cell therapy researchers from R&D through commercial manufacturing 
• How GMP-grade transfection formulations compare in terms of physical titers (GC/mL) and functional titers (TU/mL)

Leisha Kopp

Applications Scientist, Mirus Bio LLC

Leisha Kopp is an Applications Scientist at Mirus Bio LLC, a biotech company providing innovative transfection products to cell culture researchers worldwide. Leisha has over 15 years of molecular biology and mammalian cell culture experience in industrial labs, and her combined bench and business knowledge enables support of scientists in all stages of the drug discovery process – from R&D to commercial manufacturing. Leisha is a graduate of the University of Wisconsin-Madison, with key interests in biotherapeutic antibody discovery and gene therapy.

Beth Larimore

Associate Director, Viral Vector Process Development, Juno Therapeutics, Inc

Dr. Beth Larimore is Associate Director of Viral Vector Process Development at Bristol Myers Squibb and is based in Seattle. A Bay Area native, Beth earned a BA in Biological Sciences at Cornell University and a PhD in Molecular and Cellular Biology at the University of Washington, where her doctoral work focused on the basic biochemistry of a tumor suppressor protein frequently mutated in human cancers. Beth started her industry career in purification of antibody therapeutics, but has worked on viral vector process development since 2014. She has held process development roles of increasing responsibility at Amgen, Immune Design, Nohla Therapeutics, and Juno Therapeutics/BMS. She is motivated by challenging scientific and engineering problems and feels privileged to contribute to novel, life-changing therapies.

Anindya Dasgupta

Director of Vector Development, Expression Therapeutics

Anindya is the director of vector development at Expression Therapeutics. He obtained his PhD from University of South Carolina, USA. His post-doctoral training and research associateship at the school of medicine, Emory University, Atlanta, USA, were focussed on the evaluation of novel anti-cancer therapies and the development of strategies for expansion and lentivirus based bioengineering of gamma delta; T cells in serum free media. Anindya is a co-inventor of a patent on anti-cancer strategy. At his recent role at Cincinnati Childrens Hospital Medical Centre he led vector development to manufacture high titer lentiviral vectors.

Nolan Sutherland

Scientist, Bluebird Bio

Nolan Sutherland graduated from the University of Massachusetts, Amherst with a BS in Biochemistry and Molecular Biology where his research areas of focus were on molecular cloning and RNAi. Over the past 10 years he has worked in both Upstream and Downstream Process Development groups, getting his start in the area of enzyme replacement therapies before entering the gene therapy field at bluebird bio. Since that time, the majority of Nolan’s work has been focused on developing suspension-based lentiviral vector production systems for commercial manufacturing. His areas of expertise include process establishment and improvement at the miniature and bench-scales, emerging technology evaluations, transient transfection optimization, nanoparticle analysis and characterization, as well as scale-up and technology transfer. With a new role in viral vector R&D, he aims to support the development of novel vectors for in vivo use.

Watch now

SPEAKERS

Leisha Kopp

Applications Scientist, Mirus Bio LLC

Beth Larimore

Associate Director, Viral Vector Process Development, Juno Therapeutics, Inc

Anindya Dasgupta

Director of Vector Development, Expression Therapeutics

Nolan Sutherland

Scientist, Bluebird Bio

You might also like

Pairing a novel enhancer with transfection reagents to enable high-titer rAAV production

F Dziopa, R Gantier, B Reese

28 November 2023

Watch

Considerations in leveraging the Universal AAV Standard for dPCR to assess AAV genomes quantity and quality

Andrzej Noyszewski, Alex Deiulio

10 September

Watch

Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering

Lisa Prendergast

19 March

Watch

Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time

Emily Jackson-Holmes

21 May

Watch

Process in the product: a new analytical tool for AAV production optimization and monitoring

Blaž Bakalar, Ivana Petrović Koshmak

19 November

Watch